Holen Sie sich die Stockscreener-App
2.60
6.56%
0.16
Vorhandelsmarkt:
2.62
0.02
+0.77%
Schlusskurs vom Vortag:
$2.44
Offen:
$2.43
24-Stunden-Volumen:
2.46M
Relative Volume:
1.01
Marktkapitalisierung:
$253.81M
Einnahmen:
$32.31M
Nettoeinkommen (Verlust:
$-237.09M
KGV:
-0.9028
EPS:
-2.88
Netto-Cashflow:
$-219.11M
1W Leistung:
+9.94%
1M Leistung:
+3.17%
6M Leistung:
+23.81%
1J Leistung:
+23.81%
1-Tages-Spanne:
$2.36
$2.665
1-Wochen-Bereich:
$2.3265
$2.665
52-Wochen-Spanne:
$0.9101
$4.5372
Editas Medicine Inc Stock (EDIT) Company Profile
Firmenname
Editas Medicine Inc
Sektor
Branche
Telefon
617-401-9000
Adresse
11 HURLEY ST., CAMBRIDGE, MA
Vergleichen Sie EDIT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EDIT
Editas Medicine Inc
|
2.60 | 238.19M | 32.31M | -237.09M | -219.11M | -2.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-12-16 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-12-13 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2024-12-13 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-13 | Herabstufung | Truist | Buy → Hold |
| 2024-12-11 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-11-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-11-04 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2024-08-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-05-09 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-10-24 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-10-18 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-10-17 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-29 | Hochstufung | Stifel | Hold → Buy |
| 2023-06-12 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-02-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-12-13 | Eingeleitet | Citigroup | Neutral |
| 2022-12-06 | Fortgesetzt | Credit Suisse | Neutral |
| 2022-11-18 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-11-18 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-09-29 | Eingeleitet | BofA Securities | Neutral |
| 2021-10-19 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2021-09-24 | Eingeleitet | Stifel | Hold |
| 2021-09-10 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-08-09 | Hochstufung | Truist | Hold → Buy |
| 2021-08-05 | Hochstufung | Evercore ISI | Underperform → Outperform |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-05-04 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2021-04-16 | Eingeleitet | Goldman | Sell |
| 2021-03-22 | Eingeleitet | Credit Suisse | Outperform |
| 2021-03-01 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2021-02-26 | Herabstufung | Truist | Buy → Hold |
| 2021-01-19 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-01-07 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-12-10 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-11-03 | Eingeleitet | Robert W. Baird | Underperform |
| 2020-06-18 | Fortgesetzt | SunTrust | Buy |
| 2020-02-21 | Eingeleitet | Wells Fargo | Equal Weight |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2018-10-10 | Eingeleitet | Guggenheim | Neutral |
| 2018-09-21 | Eingeleitet | Raymond James | Outperform |
| 2018-05-15 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-02-13 | Eingeleitet | CLSA | Underperform |
| 2018-01-23 | Hochstufung | SunTrust | Hold → Buy |
| 2017-07-14 | Eingeleitet | SunTrust | Hold |
| 2017-03-28 | Eingeleitet | Chardan Capital Markets | Buy |
| 2016-08-10 | Hochstufung | Jefferies | Hold → Buy |
| 2016-06-02 | Eingeleitet | Jefferies | Hold |
| 2016-02-29 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2016-02-29 | Eingeleitet | JP Morgan | Neutral |
| 2016-02-29 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Editas Medicine Inc Aktie (EDIT) Neueste Nachrichten
Editas (EDIT) Down 8.3% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Cell & Gene Therapy Market to Reach USD 105.83 Billion by 2033 - openPR.com
Editas Medicine, Inc. (NASDAQ:EDIT) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Editas Medicine (EDIT) Price Target Increased by 22.78% to 4.95 - Nasdaq
Editas Medicine (EDIT) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Editas Medicine (NASDAQ:EDIT) CEO Sells $12,046.45 in Stock - MarketBeat
Trend Recap: Is Editas Medicine Inc. (8EM) stock supported by free cash flowJuly 2025 Patterns & High Accuracy Swing Trade Signals - moha.gov.vn
What valuation ratios show for Editas Medicine Inc. (8EM) stockEarnings Summary Report & Reliable Intraday Trade Alerts - Newser
CEO O'Neill Surrenders 5,603 Of Editas Medicine Inc [EDIT] - TradingView
Editas Medicine CEO Sells Shares to Meet Tax Obligations - TradingView
How Editas Medicine Inc. (8EM) stock performs in easing cyclesJuly 2025 Selloffs & Safe Entry Momentum Tips - Newser
Editas Medicine (NASDAQ:EDIT) Shares Cross Below 50-Day Moving AverageTime to Sell? - MarketBeat
Will Editas Medicine Inc. (8EM) stock beat Nasdaq index returns2025 Pullback Review & Free Verified High Yield Trade Plans - Newser
Is Editas Medicine Inc. (8EM) stock positioned for digital growth eraMarket Growth Summary & Free Fast Gain Swing Trade Alerts - Newser
CEO O'Neill Files To Sell 7,000 Of Editas Medicine Inc [EDIT] - TradingView
Euro India Fresh Foods Limited Forms Bullish Flag Upside AheadCovered Call Writing & Learn From the Strategies of Institutions - earlytimes.in
FY2025 EPS Estimates for Editas Medicine Lowered by Analyst - MarketBeat
Editas Medicine (NASDAQ:EDIT) Stock Crosses Below 50-Day Moving AverageTime to Sell? - MarketBeat
Portfolio Shifts: Is Editas Medicine Inc. stock a bargain at current levelsMarket Activity Recap & Fast Moving Stock Trade Plans - BỘ NỘI VỤ
Can Editas Medicine Inc. stock surprise with earnings upsideTrade Signal Summary & Fast Gain Stock Tips - moha.gov.vn
Editas Medicine Inc Stock Analysis and ForecastGeopolitical Risk Analysis & Access Free Risk Analysis Before You Invest - earlytimes.in
Editas Medicine (EDIT) Reports Q3 Loss, Beats Revenue Estimates - MSN
Editas Medicine price target raised to $4.60 from $4 at Clear Street - MSN
Is Editas Medicine Inc. (8EM) stock overpriced at current multiplesPortfolio Risk Report & Risk Controlled Swing Trade Alerts - newser.com
Is Editas Medicine Inc. (8EM) stock in buy zone after pullbackJuly 2025 Rallies & AI Powered Market Entry Strategies - newser.com
Will Editas Medicine Inc. (8EM) stock gain from green policies2025 Big Picture & Technical Confirmation Alerts - newser.com
Will Editas Medicine Inc. stock continue upward momentumForecast Cut & Free Technical Pattern Based Buy Signals - newser.com
How Editas Medicine Inc. (8EM) stock responds to job market shiftsJuly 2025 Snapshot & AI Enhanced Market Trend Forecasts - newser.com
Can Editas Medicine Inc. stock sustain market leadershipQuarterly Risk Review & Weekly Chart Analysis and Trade Guides - newser.com
Is Editas Medicine Inc. (8EM) stock expanding market penetrationFed Meeting & High Accuracy Swing Entry Alerts - newser.com
Does Editas Medicine Inc. (8EM) stock trade below intrinsic valueQuarterly Performance Summary & Verified Chart Pattern Trade Signals - newser.com
Why Is Editas (EDIT) Down 16.9% Since Last Earnings Report? - MSN
Is Editas Medicine Inc. stock a smart buy before Fed meetingWeekly Trading Summary & Stock Portfolio Risk Management - newser.com
Should you hold or exit Editas Medicine Inc. nowPortfolio Risk Summary & Verified Short-Term Trading Plans - newser.com
Brokers Set Expectations for Editas Medicine FY2026 Earnings - MarketBeat
Clear Street Lifts Price Target on Editas (EDIT) Medicine Amid Pipeline Progress - Insider Monkey
Finanzdaten der Editas Medicine Inc-Aktie (EDIT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):